Lantern Pharma Business Summary

Lantern Pharma Inc. (LTRN) is a clinical-stage biopharmaceutical company that leverages its proprietary RADR® artificial intelligence and machine learning platform to transform the cost and timeline of oncology drug discovery. The company generates revenue primarily through strategic licensing agreements, clinical and regulatory milestone payments, and future royalty streams from its AI-driven pipeline. Its business is divided into three primary segments: internal drug development (focusing on candidates like LP-184 and LP-300), the RADR® AI platform services for biopharma partnerships, and specialized CNS oncology through its wholly-owned subsidiary, Starlight Therapeutics. Positioned as a high-efficiency disruptor in the precision medicine market, Lantern competes with AI-biotech and oncology peers such as Black Diamond Therapeutics (BDTX), Fate Therapeutics (FATE), and BenevolentAI, distinguishing itself through its focus on rescuing and revitalizing abandoned drug candidates using genomic signatures. The company was founded by Arun K. Asaithambi, Gregory T. Tobin, and Peter L. Nara, who established the initial computational framework for its AI-driven approach. Current leadership is headed by President and CEO Panna Sharma, the former CEO of Cancer Genetics, Inc., supported by Chief Financial Officer David R. Margrave and Chief Scientific Officer Kishor G. Bhatia, PhD. The clinical strategy is further directed by Dr. Marc Chamberlain, CMO of Starlight Therapeutics, and Reggie Ewesuedo, MD, VP of Clinical Development. Lantern’s Board of Directors, chaired by Dr. Donald "Jeff" Keyser (founder of ZS Pharma), includes notable industry veterans such as Dr. Lee T. Schalop and Dr. Maria Maccecchini. The company maintains significant institutional backing from investors including BIOS Capital Management, Vanguard Group, and Renaissance Technologies.